<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>40</patient-age><report-id>PHFR2012GB006168</report-id><gender>male</gender><reactions><reaction>Accident</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>CLOZARIL</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Schizophrenia</indication></indications><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>United Kingdom</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053180_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134157</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>PHFR2012GB006168</safetyreportid>
		<primarysourcecountry>GB</primarysourcecountry>
		<occurcountry>GB</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-11-27</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-06</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHFR2012GB006168</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>Qureshi</reporterfamilyname>
			<reportercountry>GB</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>GB</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>GB</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>GB</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>RP</patientinitial>
			<patientinvestigationnumb>265764</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19711220</patientbirthdate>
			<patientsex code="1">Male</patientsex>
			<reaction>
				<primarysourcereaction>Accident</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Accident</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Accident</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Schizophrenia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2001-07-01</drugstartdate>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Accident</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Accident</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>300 mg, QD</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-27</drugstartdate>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Accident</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Accident</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>100 mg, Morning</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-28</drugstartdate>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Accident</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Accident</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHFR2012GB006168, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from <Semaphore x="1748248" class="Occupation" value="Certified Nurse Practitioner" score="1.00" ID="C71288">certified practitioner <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore></Semaphore>via <Semaphore x="385527" class="Medicine" value="Clozaril" score="1.00" ID="247865">Clozaril </Semaphore>Patient Monitoring Service on 27 Nov 2012 with follow up report received from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>on 28 Nov 2012, with follow up report received from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>on 06 Dec 2012. This report refers to 41-year old male patient (265764). The patient received <Semaphore x="385527" class="Medicine" value="Clozaril" score="1.00" ID="247865">Clozaril </Semaphore>(<Semaphore x="385490" class="Medicine" value="Clozapine" score="0.49" ID="252210">clozapine</Semaphore>) tablet for <Semaphore x="2499616" class="Disease or Finding" value="Schizophrenia" score="1.00" ID="C3362">schizophrenia </Semaphore>from 01 Jul 2001 at an unknown dose. On an unknown date, patient had an <Semaphore x="1411837" class="Disease or Finding" value="Accident" score="1.00" ID="C34340">accident </Semaphore>and was admitted to hospital. On the same day, the patient discontinued <Semaphore x="385527" class="Medicine" value="Clozaril" score="1.00" ID="247865">Clozaril</Semaphore>. The <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>reported that patient would be restarting <Semaphore x="385527" class="Medicine" value="Clozaril" score="1.00" ID="247865">Clozaril </Semaphore>next day. During follow up it was reported that the patient restarted <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="385527" class="Medicine" value="Clozaril" score="1.00" ID="247865">Clozaril </Semaphore>at a dose of 300 mg once a day (reported as yesterday) and took 100 mg in the morning 28 Nov 2012 (reported as this morning). Action taken with <Semaphore x="385527" class="Medicine" value="Clozaril" score="1.00" ID="247865">Clozaril </Semaphore>was reported as <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>temporarily interrupted. The patient then at inpatient hospital and the patient did not restarted <Semaphore x="385527" class="Medicine" value="Clozaril" score="1.00" ID="247865">Clozaril </Semaphore>until 30 Nov 2012. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>and causality of the event were not reported.Follow up report received from <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>on 28 Nov 2012: Updated suspect product information (action taken and dose).Follow up report received from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>on 06 Dec 2012: Updated <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>comment (patient did not restart <Semaphore x="385527" class="Medicine" value="Clozaril" score="1.00" ID="247865">Clozaril </Semaphore>until 30 Nov 2012).</narrativeincludeclinical>
				<sendercomment>Based on  Review of available reported data does not allow for a proper causality assessment. Reported event is unassessable.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>